MomentumOptions.com Mid-Market Update for 11/6/2017 TXMD Surges on Yuvvexy News 1:25pm (EST) TherapeuticsMD’s management team met with the FDA last Friday, to discuss the resubmission process for the drug, TX-004HR. The drug, also called Yuvvexy, is a possible treatment for dyspareunia, or moderate-to-severe vaginal pain during sexual intercourse. The company had previously received…

This content is for Momentum Options – 6 Months, Momentum Options – 1 Year and Momentum Options – 2 Years members only.
Log In Register